文献速递免疫规划卫生政策与健康促进

浙江省当前麻疹疫苗接种规划的经济学评价

An economic evaluation of the current measles vaccination program: A case study in Zhejiang Province, east China.
PubMed 文献 · Vaccine · 2019-04-27

该研究采用决策树-Markov模型,模拟浙江省2014年出生队列40年情况,从支付方角度比较当前麻疹疫苗接种规划与不接种的成本效果。

要点

  • 当前麻疹疫苗接种规划具有成本效果,BCR为6.06。
  • 规划可避免195165例麻疹病例和191例麻疹相关死亡。
  • ICER约为每避免一例病例12.91美元,每避免一例死亡13213.43美元。

核心结论

  • 当前麻疹疫苗接种规划具有成本效果并提供显著收益。

研究设计与样本

  • 采用决策树-Markov模型,参数来自已发表文献、政府文件和调查,模拟浙江省2014年出生队列40年情况。
  • 从支付方角度比较当前麻疹疫苗接种规划与不接种的预期成本和效果。

主要发现

  • 接种可避免195165例麻疹病例和191例麻疹相关死亡。
  • ICER约为每避免一例病例12.91美元,每避免一例死亡13213.43美元。
  • 模型稳健性得到验证。

关键数值与推荐

  • 成本效果阈值采用低于3倍人均GDP。
  • ICER约为每避免一例病例12.91美元,每避免一例死亡13213.43美元,具有成本效果。

临床怎么用

  • 结果可为未来投资以实现麻疹消除目标提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the economic impact of the current measles vaccination program in Zhejiang Province, east China. METHODS: A decision tree-Markov model with parameters from published literatures, government documents and surveys was developed and used to simulate over 40 years of a birth cohort in Zhejiang Province during the year 2014. The expected cost and effectiveness of the current measles vaccination program was compared against no vaccination. Costs were assessed from the payer's perspective. Benefits were defined as savings on the direct cost of measles treatment, and the effectiveness was measured according to the number of measles cases and deaths averted. The net present value (NPV), benefit-cost ratio (BCR) and incremental cost-effectiveness ratio (ICER) were also calculated. A threshold for cost-effectiveness of less than 3 times the Gross Domestic Product (GDP) per capita was used. One-way sensitivity analysis was performed to assess parameter uncertainties. RESULTS: The total vaccination cost was estimated to be $2.52 million. The BCR of the current measles program was found to be 6.06 with a NPV of $73.38 million. It was also calculated that a total of 195,165 measles cases and 191 measles-related deaths would be prevented by vaccination. The ICER was approximately $12.91 per case averted and $13,213.43 per death averted, respectively, which was cost-effective. The models were proven to be robust. CONCLUSIONS: The current measles vaccination program appeared to be cost-effective and to offer substantial benefits. The results of this analysis sought to contribute to the justification of future investments to achieve the goal of measles elimination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zeng Y, Luo M, Chen J, et al. An economic evaluation of the current measles vaccination program: A case study in Zhejiang Province, east China. Vaccine. 2019. PMID: 31040084. doi:10.1016/j.vaccine.2019.04.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。